Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Eisai Co. Ltd.

www.eisai.com

Latest From Eisai Co. Ltd.

UK's AstronauTx Gets Cash For Alzheimer's Programs

The Dementia Discovery Fund is backing the UCL spin-off's efforts to develop therapies that modulate astrocyte function.

Financing Neurology

E2082 Discontinuation May Hit Eisai's Epilepsy Succession

Fatality of healthy volunteer in early clinical trial prompts halt of all clinical work for candidate anti-epileptic, potentially hitting Eisai's product succession strategy in a core therapeutic area.

Japan Clinical Trials

Want To Fly In China‘s New Normal? Learn From Merck

Many multinationals are banking on novel drug products to capture China’s new growth spurt as it transforms to care centered on innovative therapies, although this could be a hard sell given the largely private pay nature of the market for such products. Q2 China growth at Merck & Co. however flew through the roof with the aid of a suite of newly launched products. So what made it a shining star?

China Commercial

Keeping Track: US FDA Clears Two More Biosimilars, First Non-Injectable Glucagon

The latest drug development news and highlights from our US FDA Performance Tracker.

Approvals Drug Review
See All

Company Information

Advertisement
Advertisement
UsernamePublicRestriction

Register